The use of lineage-specific hematopoietic growth factors such as GM-CSF and G-CSF shortens the duration of neuWe studied the effects of escalating doses of recombitropenia following high-dose chemotherapy and ABMT.
/l and platelet transfusion independence
factor (sTNF-r) [8] [9] [10] [11] all of which appear important in the occurred at a median of 23 and 22 days, respectively, growth of both early and late hematopoietic progenitor which was comparable to historical controls. The mean cells. IL-1 increases the proliferation and differentiation of number of bone marrow colony-forming unit granulobone marrow progenitor cells in the presence of G-CSF. cyte-macrophage (CFU-GM) per 10 5 mononuclear cells IL-1␤ also enhances the resistance of normal and neutroon day ؉21 post-ABMT was more than twice that of penic mice to gram-negative infections and enhances hemacontrol patients or patients receiving G-CSF or GMtopoietic recovery after lethal irradiation or treatment with CSF. A linear correlation was found between the dose 5-fluorouracil. 13 Enhancement of natural killer (NK) cell of IL-1␤ and endogenous concentrations of several cytoactivity by IL-1 and direct cytotoxic activity against tumor kines. These patients also displayed significantly higher cells has also been reported. 5 Preclinical studies in nonconcentrations of endogenous G-CSF compared to hishuman primates have demonstrated enhanced neutrophil torical controls receiving GM-CSF. While IL-1␤ was recovery following chemotherapy in animals receiving ILmoderately toxic and had no effect on recovery of 1␤. 14 Phase I studies in humans with normal bone marrow peripheral blood counts after ABMT, the increased function have shown that intravenous IL-1␤ is tolerable, number of bone marrow CFU-GM suggests that the with side-effects that included fever, rigors, headache and addition of G-or GM-CSF to a short course of IL-1␤ reversible hypotension. 15, 16 Of considerable interest to the may accelerate hematologic recovery.
area of bone marrow transplantation is the report of a Keywords: IL-1␤; ABMT; high-dose chemotherapy; delayed, sustained increase in platelet count following two breast cancer, cytokine or five daily intravenous infusions of IL-1␤, 15, 16 suggesting that IL-1␤ could improve platelet recovery post-ABMT.
This study was undertaken to determine the maximum tolerated dose (MTD) of human recombinant IL-1␤ given subcutaneously following high-dose chemotherapy and autologous bone marrow rescue, and to examine its effect
Patients and methods
icals, data on file). Common toxicity criteria were used to determine the MTD, which was defined as the dose level below which grade 4 toxicity was seen in any single patient, Patients or grade 3 toxicity seen in two or more patients. Sixteen patients were enrolled on the study. Patients
Bone marrow harvesting and processing were performed receiving high dose alkylating agent chemotherapy prior to high-dose therapy as described previously. 17 Purg-(cyclophosphamide, cisplatin and carmustine (BCNU)) ing of the bone marrow ex vivo was not performed. The with ABMT for high risk or metastatic breast cancer or median nucleated cell number returned to the patients was malignant melanoma were eligible. All patients had histo-2.02 × 10 8 /kg (range 1.18 to 2.73) and the median number logic confirmation of malignancy, normal performance of colony forming units (CFU)-granulocyte-macrophage status (Karnofsky score у60), normal pulmonary function (CFU-GM) was 5.6 × 10 4 /kg (range 1.1 to 14.9). All (diffusion capacity for carbon monoxide, forced expiratory patients received cyclophosphamide 1875 mg/m 2 days −6 volume in 1 s and forced vital capacity у60% of predicted), to −4 over 1 h (total dose 5625 mg/m 2 ); cisplatin cardiac ejection fraction у45%, liver enzymes р2.5 times 55 mg/m 2 /day as a continuous intravenous infusion day −6 the upper limit of the normal range and creatinine clearance to −4 (total dose 165 mg/m 2 ) and BCNU 600 mg/m 2 at у60 ml/min. Exclusion criteria consisted of the presence 5 mg/m 2 /min on day −3. 17 Bone marrow infusion was perof tumor cells in bone marrow aspiration or biopsy, central formed on day +1. The first dose of IL-1␤ was given 3 h nervous system metastases, prior therapy with cytokines after marrow infusion and then daily for a total of seven Ͻ1 month before transplant, hematocrit Ͻ0.30, positive doses. The three patients treated at the highest dose level pregnancy test, clinically significant thyroid disease or co-(32 ng/kg) also received intravenous G-CSF (filgrastim; morbid illness precluding general anesthesia for bone marAmgen, Thousand Oaks, CA, USA) starting between day row harvesting. The study was approved by the Duke Uni-8 and 16 and post-transplant until the absolute neutrophil versity Medical Center Institutional Review Board and all count was above 2.5 × 10 9 /l for 3 consecutive days. G-CSF patients provided written informed consent.
was used here as it had just become commercially available and it was felt to be unethical at that time to withhold it.
IL-1␤
Supportive care OCT-43 is a modified IL-1␤ molecule with the substitution of cysteine by serine at amino acid 71, which increases the All patients remained in reverse isolation in high efficiency stability of the molecule in vivo. The protein was expressed particle aeration (HEPA) filtered rooms until the absolute in E. coli and provided for clinical use by Otsuka America neutrophil count was Ͼ0.5 × 10 9 /l. Packed red blood cells Pharmaceutical, Rockville, MD, USA. The specific activity were transfused to maintain the hematocrit Ͼ0.42 and of OCT-43 using the human A375 cell line is 45 000 units single donor platelets were given to maintain the platelet of activity per milligram. count Ͼ25 × 10 9 /l. All blood products were irradiated to 25 Gy. Fever during neutropenia was managed according to standard antibiotic protocols.
Study design
This was an open-labelled, non-randomized dose escalation Laboratory evaluation study in which patients received a single course of IL-1␤ by subcutaneous injection for 7 days immediately following Bone marrow biopsies and aspirations were obtained prior bone marrow infusion. This short course of therapy was to entry, on day +1 and every 5 days thereafter until day chosen since the anticipated therapeutic benefit of IL-1␤ +21 to assess marrow cellularity and for assay of committed was stimulation of early progenitor cells and other, more hematopoietic progenitor cells as previously described. 18 terminally acting growth factors were becoming available. Briefly, 10 5 -10 6 light density mononuclear cells were culCohorts of three patients were treated at each dose level tured in a base mixture of 0.9% methylcellulose (Sigma, St from 4 ng/kg to 32 ng/kg. This dose range has previously Louis, MO, USA) containing equal amounts of minimal been found to be well tolerated in a phase I study of OCTessential alpha medium and Iscove's modified Dulbecco's 43 in patients with advanced cancer (Otsuka Pharmaceutmedium (Gibco, Grand Island, NY, USA), 12.5% horse serum and 12.5% heat-inactivated bovine serum. To each 35-ml plate was added 1% deionized bovine serum albumin were scored using an inverted microscope.
Diagnosis:
Serum electrolytes and complete blood counts were per-
Breast cancer 13
formed daily in all patients, and liver chemistry, serum pro- a Patients at this dose also received G-CSF 5 g/kg/day intravenously starting day +8 (two patients) or day +16 (one patient) until the PMN count was Ͼ2.5 × 10 9 /l. b Historic control patients were treated with exactly the same high-dose chemotherapy regimen and autologous bone marrow; however, did not receive growth factors post-transplant. PMN = polymorphonuclear cell count; plts = platelets; NA = not available.
samples obtained on days −6, −1, +1, +3, +8, +12 and +16.
patients were able to complete the full 7-day course of treatment at the prescribed dose. Immunoreactive TNF-␣, IL-6, M-CSF, G-CSF, GM-CSF, sTNF-r, and IL-1ra were measured using double-antibody sandwich techniques. Assay kits for the sTNF-R assay were Toxicity obtained from Bender MedSystems (Vienna, Austria), GM-CSF from Endogen (Boston, MA, USA), whereas materials Subcutaneous IL-1␤ was well tolerated and no patient for the M-CSF assay were kindly provided by Genetics required discontinuation of the study drug because of sideInstitute (Boston, MA, USA). All remaining cytokines were effects. The majority of patients experienced chills (15/16) analyzed by ELISA kits obtained from R&D Systems and fever Ͼ38.5°C (15/16) following one or more injec-(Minneapolis, MN, USA).
tions. Erythema at the injection site was seen in all patients ( Figure 1 ) and was accompanied by pain in 7/16. Local pain was ameliorated in two patients by infiltration of the site Results with local anesthetics prior to injection of IL-1␤. Three patients also experienced nausea thought to be due to The characteristics of the 16 patients enrolled in this study IL-1␤. are summarized in Table 1 . Three had metastatic malignant Hypotension has been dose-limiting following intramelanoma and 13 had stage IV breast cancer. Ten of the venous administration of IL-1␤ 15 but was observed in only 13 patients with breast cancer had received prior adjuvant one patient in our study, occurring at the highest dose level chemotherapy; none of the patients had received chemo-(32 ng/kg). This event was managed with intravenous fluids therapy for metastatic disease. Three patients received 7 and brief use of intravenous inotropic support. A second days of subcutaneous IL-1␤ at each dose level of 4, 8, 24 patient at the 32 ng/kg level experienced mild confusion and 32 ng/kg; four patients received 16 ng/kg ( Table 2 ). All (grade 3) which resolved totally after completion of the study drug. No other neurologic toxicity was noted. Five patients had positive blood cultures during the transplant period. In two patients fungal organisms were isolated (Candida albicans and Torulopsis glabrata); the former patient died of complications of candida septicemia on day +32. Three patients had bacteremia and were successfully treated with intravenous antibiotics.
There were no episodes of cardiac, pulmonary, renal or hepatic toxicity attributable to IL-1␤ during this study. One patient developed hyperbilirubinemia and right upper quadrant tenderness beginning day +23 post-transplant consistent with hepatic veno-occlusive disease. Tests of thyroid function measured on day +10 in all patients were unchanged compared to baseline values.
Hematologic recovery
Myeloid engraftment occurred in all 16 patients, with four patients treated with 16 ng/kg and the three patients treated at 24 ng/kg is shown in Figure 2 . The majority of patients had bone marrow biopsies evaluable for cellularity and morphologic assessment of hematologic recovery. Bone marrow cellularity remained low following high-dose therapy (Ͻ20%) to day +16 in most patients and myeloid maturation was slower compared to similar patients receiving GM-CSF.
1 There was morphologic evidence of recovery of all three cell lineages by day +21 in 14 of 14 patients studied. One or more biopsy samples obtained between day +1 and +21 from 11 of 16 patients showed increased fibrosis, a feature not present in any of the patients pre-transplant.
Progenitor cell assays Table 3 shows the bone marrow colony data for each dose level of IL-1␤. Although the number of patients at each dose level is small, the number of hematopoietic colonies present at day +16 and day +21 is increased at higher doses of IL-1␤ and the number of bone marrow CFU-GM present on day +21 was higher compared to historical control patients receiving no growth factor.
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The observed increase in day +21 CFU-GM colonies in the group receiving 32 ng/kg/day IL-1␤ followed by intravenous G-CSF compared to G-CSF-treated and untreated controls may be a result of the relatively high dose of IL-1␤; however, it could also suggest that sequential administration of these cytokines may have an enhanced stimulatory effect.
Most patients had detectable concentrations of cytokines at all time points analyzed with the exception of TNF-␣ (Table 4 ). In general, concentrations were highest at or following post-transplant day +3. A linear relationship was noted when a dose of IL-1␤ was compared to either G-CSF, M-CSF, IL-1ra, or sTNF-r concentrations on the day of maximal cytokine secretion during IL-1␤ administration (Figure 3) . Endogenous concentrations of G-CSF were very high as early as day +3 and declined over the next two sampling times (Figure 4) . Treatment with IL-1␤ resulted in significantly higher G-CSF concentrations on both days +3 and +8 compared to a group of historical control patients who received recombinant GM-CSF and also had absolute neutropenia on days +2 to +8. 20 Similarly, day +3 endogenous IL-6 concentrations were higher in patients treated with IL-1␤ compared to histori- higher than those in the G-CSF group. Discussion median of 23 days after marrow infusion (range 13 to 42 days). Fifteen patients were evaluable for platelet engraftment (stable platelet count Ͼ25 × 10 9 /l without The evaluation of therapy with new cytokines or hematopoietic growth factors in the setting of high-dose chemotransfusion), which occurred after a median of 22 days (range 13 to 60 days). Data on hematologic recovery at therapy and ABMT is often difficult because of the associated regimen-related toxicity. In this study we have shown each dose level is shown in Table 2 , along with data of 23 historical controls not receiving growth factors and 19 that recombinant human IL-1␤ (OCT-43) can be administered safely to such patients subcutaneously for 7 days. The patients enrolled in a phase I study of GM-CSF. 1 The time course of recovery of peripheral blood leukocytes for the major toxicities encountered were hypotension and con- fusion at the highest dose level, and severe local reactions patients. No other significant organ toxicity was identified in our patients that could be attributed to IL-1␤. at the injection site. The MTD of IL-1␤ given subcutaneously for 7 days following ABMT in this study was We did not observe any effect of IL-1␤ administered by this schedule on hematopoietic recovery compared to his-24 ng/kg/day. Toxicity at 32 ng/kg/day was not acceptable. Fever and chills were experienced by the majority of torical control patients treated with the same preparative Bone marrow readministered on day +1, subcutaneous IL-1 given on days +1 to +7. Figure 4 Comparison of median endogenous G-CSF concentrations in Figure 5 Comparison of median endogenous IL-6 concentrations in 16 14 patients receiving IL-1␤ and 20 historical control ABMT patients patients receiving IL-1␤, 20 receiving GM-CSF, and 17 receiving Greceiving recombinant GM-CSF. 20 Values were significantly different on CSF. 20 Concentrations were significantly lower in the G-CSF and GMdays 3 and 8 (P values Ͻ0.02 on each day).
CSF groups on day 3; whereas the G-CSF group was also lower on day 8 (P values Ͻ0.05). By day 12 the GM-CSF-treated patients displayed substantially higher IL-6 concentrations (P 0.021).
regimen. There appeared to be, however, a dose-related increase in day +21 bone marrow CFU-GM. In addition, we do not have data on patients treated at 32 ng/kg of IL-1␤ alone. the number of day +21 CFU-GM was greater than that seen in historical controls receiving no growth factor postNemunaitis et al 22 treated 17 patients undergoing ABMT for AML with 5 days of 10, 20 or 50 ng/kg/day recombi-ABMT. This may be due to an increase by IL-1␤ in the number of myeloid progenitor cells entering into cell cycle, nant human IL-1␤ given as daily 30-min intravenous infusions. The time required to achieve an absolute neutroas suggested by the data of Neta et al. 21 The three patients who received IL-1␤ for 7 days followed by G-CSF until phil count greater than 0.5 × 10 9 /l was 25 days compared to 34 days among historical controls who did not receive neutrophil recovery had an average number of bone marrow CFU-GM which was greater than that seen in patients we IL-1␤ post-ABMT; however, moderate toxicity was observed in all patients. Hypotension was evident in 14 of have treated previously from day +1 with G-CSF alone. Although it is tempting to speculate that the high numbers 17 patients 5 to 8 h after the infusion which required intervention in five patients, only one of which received the of bone marrow CFU-GM seen in these patients is due to synergy with G-CSF (in agreement with animal models), highest dose. In comparison, only one patient on our study required therapeutic intervention for hypotension, despite a was administered, thus providing another surrogate marker for a dose-related biologic response. Within 48 h of initiat-7-day treatment duration. The reason for this difference may be related to differences in patient population ing IL-1␤ the endogenous concentrations of G-CSF were of the order of those noted following administration of (leukemia vs solid tumors) or method of drug administration (i.v. vs s.c.).
therapeutic doses of recombinant G-CSF 26, 27 and significantly higher than those found during administration of Weisdorf et al 23 recently published an evaluation of IL-1␣ in patients undergoing bone marrow or stem cell transrecombinant GM-CSF. 20 The synergistic activity obtained when IL-1 and GM-CSF are combined ex vivo has been plantation. Daily infusions of IL-1␣ were given to patients with either Hodgkin's or non-Hodgkin's lymphoma who attributed to induction of G-CSF. 28 One interpretation of our data would be that simultaneous combination therapy received total body irradiation and either cyclophosphamide or cyclophosphamide, BCNU, and etoposide with either with IL-1␤ and G-CSF (in contrast to sequential therapy) would not be of substantial benefit due to the high degree autologous marrow or peripheral blood progenitor cell support. Doses ranged from 0.1 to 10 mg/m 2 /day given for up of G-CSF induction noted. In summary, recombinant human IL-1␤ can be administo 14 days as 6-h infusions. Infusion of IL-␣ was accompanied by chills and fever (Ͼ38.3°C) in the majority tered safely to patients following high-dose chemotherapy and ABMT. Our trial confirmed the moderate toxicity of patients as was the case in our study of IL-1␤. Hypotension (systolic blood pressure Ͻ90 mm Hg) was also comobserved with IL-1 post-ABMT. No direct effect on recovery of neutrophils or platelets was observed in our patients. mon and dose-limiting. Other toxicities included transient hyperbilirubinemia and renal insufficiency. Patients receivHowever, the presence of increased CFU-GM in the bone marrow is consistent with previous data demonstrating that ing the maximally tolerated dose of 3.0 g/m 2 /day (approximately twice the maximal dose given on our study) IL-1␤ has direct or indirect stimulatory effects on early hematopoietic cells. Dose-dependent increases in endogenwere noted to have acceleration of peripheral myeloid recovery and a shorter time to RBC transfusion indepenous plasma cytokine concentrations were found in these patients, and were significantly higher for molecules such dence but no increase in bone marrow cellularity. It is difficult to make direct comparisons of the hematopoiesis as G-CSF and IL-6 compared to patients receiving GM-CSF. Our data and that of others 14, 16, 29 suggest that combininduced by IL-1 in the trials mentioned above to the current study since many treatment variables differ. Particularly ing brief administration of IL-1␤ followed by late acting cytokines, such as G-CSF or GM-CSF may produce more important is the slower neutrophil recovery in the historic controls of these studies (34 and 24 days to achieve ANC rapid recovery of hematopoiesis and possibly affect multiple cell lineages following ABMT. The future role of Ͼ500, respectively) compared to our study (19 days).
Previous studies in humans with normal hematopoiesis combination cytokine therapy following high-dose chemotherapy will also be determined by results of the ongoing have shown that intravenously administered IL-1␤ can produce a delayed thrombocytosis after 2 15 or 5 days. 16 In a clinical evaluations of platelet specific factors (IL-11 and thrombopoietin). Should the clinical data from such trials primate ABMT model, 24 subcutaneous injection of IL-1␤, 1 to 10 g/kg twice daily for 5 days after marrow infusion suggest that hematopoiesis remains suboptimal due to a delay in early progenitor maturation, therapeutic combisignificantly shortened the duration of thrombocytopenia compared to controls. In that study, no shortening of the nations which include IL-1␤ or stem cell factor in addition to a granulocyte and megakaryocyte stimulating molecule duration of neutropenia was seen, despite the fact that neutrophilia and a modest increase in bone marrow CFU-GM may be attempted. Such studies will require detailed evaluation of bone marrow progenitor cell growth and plasma were seen in normal monkeys given the same doses of IL-1␤. One explanation for these variable results may be difcytokine levels in order to clarify the exact mechanisms operating in vivo in man during combination cytokine ferences in the cellular composition of the bone marrow in the untreated state and after 5-fluorouracil chemotherapy, therapy. total body irradiation or high-dose alkylating agent chemotherapy, in terms of responding cell populations and effector cell secretion of secondary cytokines. 14, 22 
